Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Johnson and Johnson
Fuji
Harvard Business School
Deloitte
Mallinckrodt

Generated: July 23, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,759,350

Try a free trialSee Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,759,350
Title:Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
Abstract: The pharmaceutical composition of the present invention comprises (1) a carbostyril derivative and (2) a serotonin reuptake inhibitor in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof, which is a dopamine-serotonin system stabilizer. The serotonin reuptake inhibitor may be fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline or escitalopram. The pharmaceutical composition of the present invention is useful for treating patients with mood disorders, particularly depression or major depressive disorder.
Inventor(s): Kikuchi; Tetsuro (Tokushima, JP), Iwamoto; Taro (Princeton, NJ), Hirose; Tsuyoshi (Tokushima, JP)
Assignee: Otsuka Pharmaceutical Co., Ltd. (Tokyo, JP)
Application Number:10/540,577
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,759,350
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 8,759,350
Patent Claim Types:
see list of patent claims
Composition; Use;

Drugs Protected by US Patent 8,759,350

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Otsuka ABILIFY aripiprazole SOLUTION;ORAL 021713-001 Dec 10, 2004 DISCN Yes No ➤ Sign Up ➤ Sign Up ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) ➤ Sign Up
Otsuka ABILIFY aripiprazole TABLET, ORALLY DISINTEGRATING;ORAL 021729-002 Jun 7, 2006 DISCN Yes No ➤ Sign Up ➤ Sign Up ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) ➤ Sign Up
Otsuka ABILIFY aripiprazole TABLET, ORALLY DISINTEGRATING;ORAL 021729-003 Jun 7, 2006 DISCN Yes No ➤ Sign Up ➤ Sign Up ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) ➤ Sign Up
Otsuka ABILIFY aripiprazole TABLET;ORAL 021436-006 Nov 15, 2002 AB RX Yes No ➤ Sign Up ➤ Sign Up ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,759,350

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2002-379003Dec 27, 2002
PCT Information
PCT FiledDecember 25, 2003PCT Application Number:PCT/JP03/16724
PCT Publication Date:July 22, 2004PCT Publication Number: WO2004/060374

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Queensland Health
Julphar
Moodys
Farmers Insurance
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.